The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis

A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis

November 12, 2018 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Mary Beth Humphrey, MD, PhD, FACP, is concerned that patients with rheumatic diseases who have already experienced a bone fracture are being undertreated for osteoporosis. Dr. Humphrey is a practicing rheumatologist at the Oklahoma University Health Sciences Center, director of the Rheumatology, Immunology and Allergy program within the Oklahoma University School of Medicine. She runs a lab investigating aspects of rheumatic disease, including osteoporosis and osteoimmunology.

You Might Also Like
  • RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
  • Letter: Tips to Improve Osteoporosis Screening Rates
  • BMI Feasible As Pre-Screening Tool for Osteoporosis in Women
Also By This Author
  • Finding Opportunity Through Challenge: Q&A with Vaneet K. Sandhu, MD, FACR, RhMSUS

Her concern with patients being undertreated for osteoporosis is based on a series of studies that suggest:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Only a small percentage (7% in a study on vertebral fractures) of adult patients who present with fractures, such as vertebral and hip fractures, begin anti-osteoporosis medication;1 and
  • Anti-osteoporosis treatment goes down and incidence for hip fracture goes up when a significant news report publishes information about drug holidays or side effects of anti-osteoporosis treatment.2

“I think we are missing opportunities to treat patients who are presenting with fractures—this should be our most important group to treat,” Dr. Humphrey says.

Alternatively, a recent study suggests some physicians may be overtreating patients with anti-osteoporosis medications in the absence of osteoporosis.3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Overtreatment [of osteoporosis] is something we worry about,” Dr. Humphrey says. She notes it’s reassuring to read in this study that rheumatologists were among the physicians with the lowest rates of overtreatment. However in the study, family practitioners were found to be overtreating patients without osteoporosis, defined as a T score < -2.5 or a Fracture Risk Assessment Tool (FRAX) analysis with increased risk of fracture. All physicians, including rheumatologists, should be aware of this risk.

Talk About Bone Health
Dedicated discussion between rheumatologists and their patients about osteoporosis needs to target a patient’s specific risk and begin with screening. Dual-energy X-ray absorptiometry (DXA) is the preferred method to test bone density; however, insurance coverage for it varies.

Dr. Humphrey says FRAX can also be effective in determining if a patient is at low, moderate or high risk for bone fragility and fracture caused by osteoporosis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

She suggests screening results should be discussed with the patient in the context of established guidance, such as the ACR’s 2017 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, which Dr. Humphrey co-authored.

“It’s easy to pull up the guideline electronically while talking to a patient to guide discussion based on osteoporosis risk, lifestyle choices and comorbidities, which can dictate treatment options,” Dr. Humphrey says.

Strategize for Optimal Treatment
After a rheumatologist identifies a patient is at high risk for fracture, they should conduct separate discussion about medications. Important points to cover with patients in this discussion include:

  • Any previous fractures, including the fracture type and severity;
  • Preferred medication options; and
  • Length of therapy.

Several different classes of anti-osteoporosis drugs exist. These treatments include oral bisphosphonates; IV bisphosphonates; parathyroid hormone analogs, such as teriparatide and abaloparatide; and denosumab. Additional options include raloxifene for postmenopausal women when other medications are not deemed appropriate.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: bone, fracture risk, Fractures, Osteoporosis, patient care

You Might Also Like:
  • RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
  • Letter: Tips to Improve Osteoporosis Screening Rates
  • BMI Feasible As Pre-Screening Tool for Osteoporosis in Women
  • Osteoporosis Screening Is Underutilized Despite Recommendations

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)